Hemodynamic noninvasive skin cancer diagnostics

Ended Project Grant Awarded Last action

Award ID
R44CA203038
Recipient
Awarding agency
Obligated
$10,006,144

Award facts

Assistance listing
93.394 Cancer Detection and Diagnosis Research
Completion date
Originally
Place of performance
California, USA

Award details come from USAspending.gov.

Transactions

Action Obligated Date
Amendment $0
Amendment $742,845
Amendment $757,314
Amendment Pivotal clinical study of the truscore device for non-invasive skin cancer diagnostics - description (provided by applicant): skin cancer is the most common… $757,314
Amendment -$31,301
Amendment Hemodynamic noninvasive skin cancer diagnostics - description (provided by applicant): skin cancer is the most common form of cancer in the US, each year… -$31,301
Amendment -$31,301
Amendment -$31,301
Amendment Pivotal clinical study of the truscore device for non-invasive skin cancer diagnostics - description (provided by applicant): skin cancer is the most common… $1,499,425
Amendment $1,499,425
Amendment $1,499,425
Amendment Hemodynamic noninvasive skin cancer diagnostics - description (provided by applicant): skin cancer is the most common form of cancer in the US, each year… $1,499,425
Amendment $0
Amendment $0
Amendment $0
Amendment $0
Amendment $2,000
Amendment $896,930
Amendment $521,409
Amendment -$521,410
Original award $977,245
Show all 21

Quick answers

Who received award R44CA203038?

R44CA203038 was awarded to Veriskin, Inc. by National Cancer Institute (National Institutes of Health) on May 1, 2016.

How much is award R44CA203038 worth?

$10,006,144 has been obligated on R44CA203038.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award
Try for free Login